Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Efficacy of 『Opast Tablet』for Neurologic Claudication in Patients With Lumbar Spinal Stenosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is fully understand the clinical trial and obtained informed consent.~* Age 20-75years.~* Patients with a confirmed diagnosis of waist of spinal canal stenosis.~* Limb pain caused by waist of spinal canal stenosis index of VAS 3 or more patients.~* Subject who has numbness symptom on lower extremity(ies) and intermittent claudication that are due to spinal canal stenosis and fulfills both of following criteria at the same time~  * When screening visit, a medical examination by interview had the following symptoms in subjects ; In daily life walking, when walked by within 20 minutes on flatland, the subject can feel the symptoms (numbness, pain or tightness on lower extremity(ies), etc.)~    * Subject who experienced numbness, pain, tightness or other similar symptom(s) on lower extremity within 15 minutes from test start at baseline(D1) evaluation.~      * speed: 3km/hr, grade:0%, posture: should keep their lumbar spinal extended~Exclusion Criteria:~* Pregnant or lactating women of childbearing potential not employing adequate contraception.~* Patients who have the hereditary problem of galactose intolerance, Lapp lactase deficiency or grape sugar-galactose absorption defect.~* Patients with systemic disease affecting the lower limbs.~* Patients who have cauda equina syndrome.~* Patients with acute osteoporosis compression fracture in lumbar vertebra.~* Patients who have gait disturbance of degenerative arthritis by hip joint, knee joint, ankle joint.~* At least one month before the start of the study, patients use of steroid drug except lumbar dura mater.~* 6 month before the start of the study, patients with ischaemic disease in blood vessel, lung or the coronary artery, varicose artery.~* Patients with lumbar necrosis in head of femur avascular necrosis, necrotic foot ulcer.~* Patients surgery by lumbar fusion and lumbar decompression.~* Patients with renal disease or need to hemodialysis.~  * serum creatinine \> 2xUNL~* 3 month before the start of the study, patients participated in another clinical research.~* Patients with difficult understanding spirit incompetence, lack of will or language barrier.~* The investigator judged seriously ill patients need surgery patient.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Limaprost & Placebo (Type: EXPERIMENTAL): Limaprost 5㎍ tablet and a capsule of Pegabalin-Placebo thrice a day for 8 weeks.
- Pregabalin & Placebo (Type: ACTIVE_COMPARATOR): Pregabalin 75mg capsule and a tablet of Limaprost-Placebo thrice a day for 8 weeks.
- Limaprost+Pregabalin (Type: ACTIVE_COMPARATOR): Limaprost 5㎍ tablet and Pregabalin 75mg capsule thrice a day for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).